Personalised Medicine: implication and perspectives in the field of occupational health.


Journal

La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176

Informations de publication

Date de publication:
25 Nov 2020
Historique:
received: 13 11 2020
accepted: 25 11 2020
entrez: 14 12 2020
pubmed: 15 12 2020
medline: 16 12 2020
Statut: epublish

Résumé

"Personalised medicine" relies on identifying and integrating individual variability in genomic, biological, and physiological parameters, as well as in environmental and lifestyle factors, to define "individually" targeted disease prevention and treatment. Although innovative "omic" technologies supported the application of personalised medicine in clinical, oncological, and pharmacological settings, its role in occupational health practice and research is still in a developing phase. Occupational personalised approaches have been currently applied in experimental settings and in conditions of unpredictable risks, e.g.. war missions and space flights, where it is essential to avoid disease manifestations and therapy failure. However, a debate is necessary as to whether personalized medicine may be even more important to support a redefinition of the risk assessment processes taking into consideration the complex interaction between occupational and individual factors. Indeed, "omic" techniques can be helpful to understand the hazardous properties of the xenobiotics, dose-response relationships through a deeper elucidation of the exposure-disease pathways and internal doses of exposure. Overall, this may guide the adoption/implementation of primary preventive measures protective for the vast majority of the population, including most susceptible subgroups. However, the application of personalised medicine into occupational health requires overcoming some practical, ethical, legal, economical, and socio-political issues, particularly concerning the protection of privacy, and the risk of discrimination that the workers may experience. In this scenario, the concerted action of academic, industry, governmental, and stakeholder representatives should be encouraged to improve research aimed to guide effective and sustainable implementation of personalised medicine in occupational health fields.

Identifiants

pubmed: 33311418
doi: 10.23749/mdl.v111i6.10947
pmc: PMC7809984
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-444

Commentaires et corrections

Type : CommentIn

Références

Front Pharmacol. 2020 May 15;11:722
pubmed: 32528284
JAMA. 2016 Oct 4;316(13):1357-1358
pubmed: 27541310
Semin Perinatol. 2015 Dec;39(8):623-31
pubmed: 26521050
Sci Transl Med. 2011 Jan 12;3(65):65ra4
pubmed: 21228398
Carcinogenesis. 2006 Oct;27(10):2083-9
pubmed: 16728435
Toxicology. 2013 Oct 4;312:158-65
pubmed: 23978457
JAMA Oncol. 2016 Jan;2(1):13-4
pubmed: 26540172
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Annu Rev Public Health. 2018 Apr 1;39:153-168
pubmed: 29166244
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
EPMA J. 2018 Nov 23;9(4):345-353
pubmed: 30538786
Occup Environ Med. 2010 Feb;67(2):136-43
pubmed: 19933307
J Oncol Pract. 2017 Feb;13(2):e108-e119
pubmed: 27601506
Carcinogenesis. 2009 Jan;30(1):50-8
pubmed: 18978339
Expert Rev Precis Med Drug Dev. 2017;2(1):33-45
pubmed: 29276780
Mutat Res. 2004 Mar 14;558(1-2):35-44
pubmed: 15036117
JAMA. 2016 Feb 9;315(6):613
pubmed: 26864420
Am J Prev Med. 2016 Mar;50(3):398-401
pubmed: 26547538
JAMA Oncol. 2016 Nov 01;2(11):1452-1459
pubmed: 27273579
Sci Rep. 2020 Jan 15;10(1):331
pubmed: 31942019
J Occup Environ Med. 2017 Nov;59(11):e209-e214
pubmed: 28753135
J Occup Environ Med. 2016 Aug;58(8 Suppl 1):S12-21
pubmed: 27501099
J Mol Diagn. 2013 Jul;15(4):415-53
pubmed: 23562183
Diabetes Ther. 2020 Feb;11(2):411-422
pubmed: 31916214
Respir Res. 2019 Jun 6;20(1):113
pubmed: 31170986
JAMA Netw Open. 2020 Feb 5;3(2):e1920833
pubmed: 32049290
J Transl Med. 2017 Jun 17;15(1):139
pubmed: 28623955
Chem Biol Interact. 2005 May 30;153-154:123-7
pubmed: 15935808
Int J Breast Cancer. 2018 May 9;2018:4809183
pubmed: 29862084
AMA J Ethics. 2018 Sep 1;20(9):E849-856
pubmed: 30242816
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14173-14175
pubmed: 27911833
Mil Med. 2015 Oct;180(10 Suppl):34-48
pubmed: 26444891
N Engl J Med. 2015 Jan 29;372(5):397-9
pubmed: 25629736
Lancet Respir Med. 2020 Jan;8(1):65-124
pubmed: 31570318
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Nat Rev Clin Oncol. 2018 Aug;15(8):477-494
pubmed: 29872177
Diabetologia. 2017 May;60(5):793-799
pubmed: 28175964
Am Soc Clin Oncol Educ Book. 2017;37:160-169
pubmed: 28561651
Eur Respir J. 2017 Oct 19;50(4):
pubmed: 29051268
J Occup Environ Hyg. 2015;12 Suppl 1:S69-81
pubmed: 26583908
Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S3-S13
pubmed: 28958911
Lancet Diabetes Endocrinol. 2018 Aug;6(8):637-646
pubmed: 29880308
N Engl J Med. 2009 Feb 19;360(8):753-64
pubmed: 19228618
Diabetes Res Clin Pract. 2016 Jul;117:12-21
pubmed: 27329017
Nat Rev Clin Oncol. 2018 Jun;15(6):348-349
pubmed: 29599475
Science. 2004 Dec 3;306(5702):1774-6
pubmed: 15576619
Immunol Cell Biol. 2021 Feb;99(2):168-176
pubmed: 32924178
J Occup Environ Hyg. 2015;12 Suppl 1:S55-68
pubmed: 26097979
Pharmacogenet Genomics. 2015 Jan;25(1):41-7
pubmed: 25370453
PLoS One. 2015 Oct 21;10(10):e0140764
pubmed: 26489089
Health Aff (Millwood). 2018 May;37(5):694-701
pubmed: 29733705
Clin Perinatol. 2018 Mar;45(1):41-59
pubmed: 29406006
Pharmacotherapy. 2017 Sep;37(9):1150-1163
pubmed: 28672100
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Nat Rev Clin Oncol. 2020 Oct;17(10):595-610
pubmed: 32572208
Trends Biotechnol. 2020 May;38(5):497-518
pubmed: 31980301
Cancer Res. 2005 Oct 15;65(20):9574-81
pubmed: 16230423
N Engl J Med. 2015 Jun 4;372(23):2229-34
pubmed: 26014593
Intensive Care Med. 2019 May;45(5):627-636
pubmed: 30847515
N Engl J Med. 2006 Aug 3;355(5):467-77
pubmed: 16885550
Redox Biol. 2015 Aug;5:71-79
pubmed: 25863726
Front Cell Dev Biol. 2020 Feb 11;8:48
pubmed: 32117976
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:105-122
pubmed: 28961067
Sci Transl Med. 2015 Aug 12;7(300):300ps17
pubmed: 26268311
Lancet Diabetes Endocrinol. 2018 Nov;6(11):891-900
pubmed: 29699867
Toxicol Sci. 2006 Feb;89(2):431-7
pubmed: 16251483
Environ Health Perspect. 2003 Aug;111(11):1429-38
pubmed: 12928151
Biometals. 2005 Dec;18(6):603-13
pubmed: 16388400
Cancer Res. 2007 Feb 1;67(3):876-80
pubmed: 17283117
Cancers (Basel). 2020 Feb 19;12(2):
pubmed: 32092958
Chem Biol Interact. 2010 Mar 19;184(1-2):86-93
pubmed: 20026094
Genome Med. 2019 Nov 21;11(1):72
pubmed: 31752965

Auteurs

Valentina Bollati (V)

EPIGET LAB, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy. valentina.bollati@unimi.it.

Luca Ferrari (L)

EPIGET LAB, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy. luca.ferrari@unimi.it.

Veruscka Leso (V)

Section of Occupational Medicine, Department of Public Health, Università degli Studi di Napoli Federico II, Napoli, Italy. veruscka.leso@unina.it.

Ivo Iavicoli (I)

Section of Occupational Medicine, Department of Public Health, Università degli Studi di Napoli Federico II, Napoli, Italy. ivo.iavicoli@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH